Fiera Capital Corp Decreases Stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Fiera Capital Corp trimmed its position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) by 4.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 216,068 shares of the company's stock after selling 9,642 shares during the quarter. Fiera Capital Corp owned 0.39% of PROCEPT BioRobotics worth $12,588,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in PRCT. ANTIPODES PARTNERS Ltd bought a new stake in shares of PROCEPT BioRobotics during the 1st quarter valued at $30,000. Thematics Asset Management bought a new stake in shares of PROCEPT BioRobotics during the 4th quarter valued at $46,000. CWM LLC boosted its holdings in shares of PROCEPT BioRobotics by 69.5% during the 1st quarter. CWM LLC now owns 873 shares of the company's stock valued at $51,000 after buying an additional 358 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of PROCEPT BioRobotics by 32.5% during the 1st quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company's stock valued at $64,000 after buying an additional 270 shares in the last quarter. Finally, IFP Advisors Inc boosted its holdings in shares of PROCEPT BioRobotics by 358.9% during the 1st quarter. IFP Advisors Inc now owns 3,313 shares of the company's stock valued at $193,000 after buying an additional 2,591 shares in the last quarter. 89.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at PROCEPT BioRobotics

In related news, Director Antal Rohit Desai sold 25,000 shares of PROCEPT BioRobotics stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $61.49, for a total value of $1,537,250.00. Following the sale, the director owned 14,363 shares of the company's stock, valued at approximately $883,180.87. This trade represents a 63.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 100,000 shares of company stock valued at $6,271,250. 6.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PRCT. Truist Financial dropped their price target on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, April 11th. Wall Street Zen lowered shares of PROCEPT BioRobotics from a "hold" rating to a "sell" rating in a research report on Saturday, July 12th. Bank of America lowered their target price on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a report on Friday, April 25th. Morgan Stanley reduced their price target on shares of PROCEPT BioRobotics from $71.00 to $68.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 15th. Finally, Oppenheimer started coverage on shares of PROCEPT BioRobotics in a report on Monday, July 7th. They issued a "market perform" rating on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, PROCEPT BioRobotics currently has an average rating of "Moderate Buy" and an average price target of $84.13.

PROCEPT BioRobotics Price Performance

PROCEPT BioRobotics stock traded up $1.45 during trading on Friday, reaching $49.96. The company had a trading volume of 1,284,652 shares, compared to its average volume of 978,010. The firm's 50-day simple moving average is $58.65 and its 200 day simple moving average is $60.45. PROCEPT BioRobotics Corporation has a 1-year low of $47.04 and a 1-year high of $103.81. The firm has a market capitalization of $2.76 billion, a PE ratio of -29.39 and a beta of 1.07. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.75 and a current ratio of 8.95.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).